GSDME

Across TCGA pan-cancer cohorts, GSDME RNA is linked to patient survival in 20 of 34 cancer types, making it the most broadly survival-associated GSDME data layer compared with 4 for mutation status and 5 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher GSDME RNA is associated with worse overall survival. In most high-consensus cancer types, elevated GSDME expression acts as an unfavorable survival marker, although some lineages such as ACC and KIRP show a favorable association.

STAD, ACC, and LIHC are the cancer types where GSDME RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	II,III,IV	0.329	0.546	<.001	80	view →
ACC	DFS	Median	All	0.615	0.298	<.001	60	view →
LIHC	OS	Tertile	All	0.407	0.602	<.001	54	view →
KIRP	OS	Quartile	II,III,IV	0.971	0.703	.007	39	view →
HNSC	OS	Quartile	IV	0.232	0.485	.006	37	view →
ESCA	OS	Tertile	All	1.000	0.307	.003	30	view →
LUSC	DFS	Quartile	III,IV	0.328	0.652	.013	26	view →
KIRC	OS	Median	All	0.765	0.853	.011	19	view →
LAML	DFS	Median	All	0.431	0.701	.004	14	view →
COAD	DFS	Tertile	IV	0.190	0.566	.019	8	view →
MESO	DFS	Median	III,IV	0.245	0.596	.017	6	view →
THCA	OS	Median	IV	0.683	1.000	.019	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 20 lineages.

GSDME–STAD (OS)

Open the STAD breakdown →